Investment firm Truist has revised its price target for Medpace (MEDP, Financial), reducing it from $333 to $300. This decision follows a detailed conversation with Medpace's management regarding the company's first-quarter performance, financial guidance for 2025, current booking trends, and future growth prospects.
While Medpace's leadership expressed assurance in reaching their revenue outlook for 2025, they conveyed more caution regarding booking trends. Despite these mixed signals, Truist continues to hold a 'Hold' rating on the shares of Medpace, underscoring a neutral stance on its near-term stock performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Medpace Holdings Inc (MEDP, Financial) is $312.93 with a high estimate of $404.00 and a low estimate of $280.00. The average target implies an upside of 10.86% from the current price of $282.28. More detailed estimate data can be found on the Medpace Holdings Inc (MEDP) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Medpace Holdings Inc's (MEDP, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Medpace Holdings Inc (MEDP, Financial) in one year is $365.69, suggesting a upside of 29.55% from the current price of $282.28. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Medpace Holdings Inc (MEDP) Summary page.
